This is a request for Phase I funding to test the hypothesis that glycoprotein (GP) V is the thrombin receptor on platelets. Recent data indicate that thrombin, acting proteolytically at a receptor on the platelet surface, is the physiologically important agonist to activate platelets and to initiate arterial thrombus formation. Previous studies from the applicant's laboratory have shown that the only detectable thrombin substrate on the platelet membrane surface is GP V. In the proposed study, GP V will be cloned to deduce the amino acid sequence of this protein.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL044251-01
Application #
3501738
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1990-03-15
Project End
1990-09-14
Budget Start
1990-03-15
Budget End
1990-09-14
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Cor Therapeutics, Inc.
Department
Type
DUNS #
City
South San Francisco
State
CA
Country
United States
Zip Code
94080